{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:13:58Z","timestamp":1790687638525,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"3-V Biosciences"},{"DOI":"10.13039\/100015124","name":"Abbott Molecular","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015124","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Advanced Biological Laboratories"},{"name":"Afimmune"},{"name":"Aicuris"},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Aligos Therapeutics"},{"name":"Altimmune"},{"name":"AMRA Medical"},{"name":"Arbutus Biopharma"},{"DOI":"10.13039\/100014931","name":"Arrowhead Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014931","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Assembly Biosciences"},{"DOI":"10.13039\/100004324","name":"Astellas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"Astra-Zeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squib","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chimerix"},{"name":"Cirius Therapeutics"},{"name":"Cocrystal Pharma, Inc."},{"name":"Conatus Pharmaceuticals, Inc."},{"name":"ConSynance"},{"name":"Covance"},{"name":"DDL Diagnostics"},{"name":"CTI Clinical Trial and Consulting Services"},{"name":"Cirius Therapeutics Inc."},{"name":"ContraVir"},{"name":"Cymabay"},{"name":"DeuteRx"},{"name":"DiaPharma"},{"name":"DS Biopharma"},{"name":"Durect"},{"DOI":"10.13039\/100014421","name":"EA Pharma Co., Ltd.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014421","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Echosens"},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Enanta Pharmaceuticals, Inc."},{"name":"Enyo Pharma"},{"name":"e.scopics"},{"name":"Exalenz"},{"DOI":"10.13039\/501100004914","name":"Ferring Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004914","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fractyl"},{"name":"Galectin Therapeutics"},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Genesis Imaging Services"},{"name":"Genfit"},{"name":"Genkyotex"},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Glympse Bio"},{"name":"Hepatitis B Foundation"},{"name":"HepQuant"},{"name":"HighTide Therapeutics"},{"name":"HistoIndex Pte Ltd"},{"name":"Humedics GmbH"},{"name":"ICON Clinical Research"},{"name":"Immuron"},{"name":"Intercept Pharmaceuticals"},{"name":"Inventiva"},{"DOI":"10.13039\/100010721","name":"Ironwood Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010721","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Janssen"},{"name":"LabCorp"},{"name":"Madrigal Pharmaceuticals"},{"DOI":"10.13039\/100014468","name":"Mallinckrodt Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014468","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MEDIAN Technologies"},{"name":"MediciNova"},{"name":"Medivir"},{"name":"Merck Laboratories"},{"name":"Metacrine"},{"name":"Microbiotix"},{"name":"Mirum"},{"name":"Morphic Therapeutic"},{"DOI":"10.13039\/100016259","name":"Mylan","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016259","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NGM Biopharmaceuticals"},{"name":"Nimbus Therapeutics"},{"name":"Nitto Denko Technical Corp"},{"name":"Nordic Bioscience"},{"name":"Northsea Therapeutics"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Novo Nordisk Inc."},{"name":"Nusirt"},{"name":"OWL Metabolomics"},{"name":"Perspectum Diagnostics"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pliant Therapeutics"},{"name":"PPD Inc."},{"name":"ProSciento"},{"DOI":"10.13039\/100015627","name":"Quest Diagnostics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015627","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Raptor Pharmaceuticals"},{"name":"Resonance Health"},{"name":"Resoundant"},{"name":"Roche Molecular Systems"},{"name":"Roivant Sciences"},{"name":"RuiYi"},{"name":"SeraCare"},{"DOI":"10.13039\/100007343","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007343","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Springbank Pharma"},{"name":"Somalogic"},{"name":"Syneos Health"},{"DOI":"10.13039\/100007723","name":"Takeda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"name":"TARGET PharmaSolutions"},{"name":"Teva Pharmaceuticals"},{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]},{"name":"VLVBio"},{"name":"Zafgen"},{"name":"Zealand Pharma"},{"name":"Duke Divisions of Gastroenterology"},{"name":"Integrative Medicine"},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["U01DK061713"],"award-info":[{"award-number":["U01DK061713"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.jhep.2020.04.030","type":"journal-article","created":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T15:18:09Z","timestamp":1588000689000},"page":"680-693","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum"],"prefix":"10.1016","volume":"73","author":[{"given":"Oliver","family":"Glass","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Filozof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Noureddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Berner-Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmer","family":"Schabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie O.","family":"Omokaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rn M.","family":"Schattenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1823-1598","authenticated-orcid":false,"given":"Katherine","family":"Barradas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7527-4714","authenticated-orcid":false,"given":"Sven","family":"Francque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5001-8618","authenticated-orcid":false,"given":"Manal F.","family":"Abdelmalek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2020.04.030_bib1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.04.030_bib2","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/hep.29607","article-title":"Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science","volume":"67","author":"Siddiqui","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.04.030_bib3","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/hep.30672","article-title":"Defining improvement in nonalcoholic steatohepatitis for treatment trial endpoints: recommendations from the liver forum","volume":"70","author":"Cheung","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.04.030_bib4","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2020.04.030_bib5","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.cgh.2018.06.011","article-title":"Rates of and factors associated with placebo response in trials of pharmacotherapies for nonalcoholic steatohepatitis: systematic review and meta-analysis","volume":"17","author":"Han","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2020.04.030_bib6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/13543784.2020.1716333","article-title":"Effectiveness of lifestyle interventions in NAFLD (nonalcoholic fatty liver disease) \u2013 how are clinical trials affected?","volume":"29","author":"Michel","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jhep.2020.04.030_bib7","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1053\/j.gastro.2017.07.024","article-title":"Baseline parameters in clinical trials for nonalcoholic steatohepatitis: recommendations from the liver forum","volume":"153","author":"Patel","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2020.04.030_bib8","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/clpt.2009.140","article-title":"The forum for collaborative HIV research: a model for an integrated and inclusive approach to clinical research and drug development","volume":"86","author":"Miller","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jhep.2020.04.030_bib9","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.04.030_bib10","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.04.030_bib11","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2020.04.030_bib12","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jclinepi.2013.08.015","article-title":"Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects","volume":"67","author":"McCambridge","year":"2014","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jhep.2020.04.030_bib13","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/oby.21456","article-title":"Placebo effects in obesity research","volume":"24","author":"Fontaine","year":"2016","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.jhep.2020.04.030_bib14","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12881-016-0352-9","article-title":"Physical activity and sedentary behavior can modulate the effect of the PNPLA3 variant on childhood NAFLD: a case-control study in a Chinese population","volume":"17","author":"Wang","year":"2016","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.jhep.2020.04.030_bib15","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A\u00a0placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2020.04.030_bib16","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1001\/jamainternmed.2019.2248","article-title":"Association of weight loss interventions with changes in biomarkers of nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"179","author":"Koutoukidis","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jhep.2020.04.030_bib17","doi-asserted-by":"crossref","first-page":"e0134172","DOI":"10.1371\/journal.pone.0134172","article-title":"Efficacy of berberine in patients with non-alcoholic fatty liver disease","volume":"10","author":"Yan","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2020.04.030_bib18","doi-asserted-by":"crossref","first-page":"e0175717","DOI":"10.1371\/journal.pone.0175717","article-title":"A\u00a0randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis","volume":"12","author":"McPherson","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2020.04.030_bib19","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2020.04.030_bib20","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1007\/s00125-013-3149-9","article-title":"The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial","volume":"57","author":"Takeshita","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.jhep.2020.04.030_bib21","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2036.2008.03723.x","article-title":"Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis","volume":"28","author":"Idilman","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2020.04.030_bib22","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.cct.2008.09.003","article-title":"Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design","volume":"30","author":"Chalasani","year":"2009","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.jhep.2020.04.030_bib23","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2020.04.030_bib24","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2020.04.030_bib25","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2020.04.030_bib26","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jhep.2016.04.021","article-title":"Sitagliptin vs. placebo for non-alcoholic fatty liver disease: a randomized controlled trial","volume":"65","author":"Cui","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.04.030_bib27","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2020.04.030_bib28","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/j.cgh.2014.04.038","article-title":"The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease","volume":"12","author":"Safadi","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2020.04.030_bib29","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3748\/wjg.v23.i1.141","article-title":"Sitagliptin in patients with non-alcoholic steatohepatitis: a randomized, placebo-controlled trial","volume":"23","author":"Joy","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2020.04.030_bib30","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/apt.13816","article-title":"Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis","volume":"44","author":"Harrison","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2020.04.030_bib31","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.cct.2016.02.012","article-title":"Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR phase 2b study design","volume":"47","author":"Friedman","year":"2016","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.jhep.2020.04.030_bib32","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2020.04.030_bib33","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jhep.2015.08.038","article-title":"Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis","volume":"64","author":"Armstrong","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.04.030_bib34","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/hep.27647","article-title":"Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)","volume":"61","author":"Loomba","year":"2015","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2020.04.030_bib35","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1123\/jpah.2015-0038","article-title":"Participation in types of physical activities among US adults--National Health and Nutrition Examination Survey 1999-2006","volume":"12","author":"Dai","year":"2015","journal-title":"J\u00a0Phys Act Health"},{"key":"10.1016\/j.jhep.2020.04.030_bib36","first-page":"155","article-title":"Physical activity monitoring in patients with chronic obstructive pulmonary disease","volume":"1","author":"Liao","year":"2014","journal-title":"Chronic Obstr Pulm Dis"},{"key":"10.1016\/j.jhep.2020.04.030_bib37","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/oxfordjournals.aje.a114416","article-title":"A\u00a0data-based approach to diet questionnaire design and testing","volume":"124","author":"Block","year":"1986","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jhep.2020.04.030_bib38","doi-asserted-by":"crossref","first-page":"922","DOI":"10.2337\/dc13-2195","article-title":"Diabetes prevention in the real world: effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes and of the impact of adherence to guideline recommendations. A systematic review and meta-analysis","volume":"37","author":"Dunkley","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jhep.2020.04.030_bib39","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.jhep.2008.02.011","article-title":"Fructose consumption as a risk factor for non-alcoholic fatty liver disease","volume":"48","author":"Ouyang","year":"2008","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.04.030_bib40","series-title":"Guidance for Industry: Diabetes Mellitus\u2014Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes","year":"2008"},{"key":"10.1016\/j.jhep.2020.04.030_bib41","series-title":"Guideline on Clinical Investigation of Medicinal Products in the Treatment or Prevention of Diabetes Mellitus","year":"2012"},{"key":"10.1016\/j.jhep.2020.04.030_bib42","series-title":"Guidelines for the Clinical Evaluation of Weight-Control Drugs","year":"1996"},{"key":"10.1016\/j.jhep.2020.04.030_bib43","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/obr.12111","article-title":"Association of run-in periods with weight loss in obesity randomized controlled trials","volume":"15","author":"Affuso","year":"2014","journal-title":"Obes Rev"},{"key":"10.1016\/j.jhep.2020.04.030_bib44","series-title":"Endocrinologic and Metabolic Drugs Advisory Subcommittee: Proceedings","year":"2004"},{"key":"10.1016\/j.jhep.2020.04.030_bib45","series-title":"Guideline on Clinical Evaluation of Medicinal Products Used in Weight Management","year":"2016"},{"key":"10.1016\/j.jhep.2020.04.030_bib46","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jhep.2015.02.022","article-title":"Effect of aerobic exercise training dose on liver fat and visceral adiposity","volume":"63","author":"Keating","year":"2015","journal-title":"J\u00a0Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827820302749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827820302749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:40:59Z","timestamp":1759174859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827820302749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0168827820302749"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2020.04.030","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2020.04.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}